Today: 20 July 2026
Browse Category

NASDAQ:HIMS 29 September 2025 - 2 June 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Hims Kicks Off $1.15 Billion Global Push; Shares Hold Back

Hims Kicks Off $1.15 Billion Global Push; Shares Hold Back

Hims & Hers Health shares moved lower Tuesday morning after the company announced it wrapped up its buyout of Australia’s Eucalyptus. The telehealth firm called the deal part of a push for expansion outside the U.S. as changes keep coming to its American weight-loss business. Hims was down 0.9% at $27.52 in early trade after starting the session at $27.93 and hitting a high of $28.85.
2 June 2026
·
Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Investors eye Hims & Hers Health Inc. as it approaches Monday’s first-quarter results, with attention locked on the future of its weight-loss segment—especially after the company pulled back from widely promoted compounded GLP-1 drugs. Earnings will post after the U.S. markets close, followed by a 5 p.m. ET conference call, according to Hims & Hers.
11 May 2026
····
Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Surges Ahead of Earnings as Omnicell Lags in Healthcare Tech Shakeout

Hims & Hers Health jumped another 8.9% by 10:25 a.m. EDT on Monday, pushing its winning streak further. Omnicell and Privia Health only managed gains of less than 1%. Telehealth stocks like Hims & Hers remain in focus after Yahoo Finance highlighted the company’s 48.3% surge over the past week ahead of its earnings release set for May 11.
20 April 2026
····
Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares surged 5.9% to finish at $23.47 on Tuesday, building on a two-day rally that’s now hit roughly 49%. The telehealth firm had closed at $15.74 back on March 6, then soared to $22.16 at Monday’s close. During Tuesday’s session, the stock swung from $22.43 up to $26.03 before easing back to settle below its session peak, following news of a fresh distribution deal with Novo Nordisk.
11 March 2026
··
Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Hims & Hers announced Saturday it’s discontinuing access to its compounded semaglutide pill—previously sold at $49 a month—after U.S. regulators threatened enforcement on off-brand weight-loss treatments. Shares in Hims dropped 15.9% Friday, closing at $19.36. https://www.reuters.com/legal/litigation/hims-hers-stop-offering-compounded-semaglutide-pill-after-fda-crackdown-2026-02-07/ https://finance.yahoo.com/quote/HIMS/history/
8 February 2026
··
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Shares of Hims & Hers Health dropped 3.8% to $23.48 in premarket trading on Friday. The slide came after FDA Commissioner Marty Makary warned the agency would act quickly against firms mass-marketing “illegal copycat drugs.” The stock had already fallen 3.8% on Thursday and plunged nearly 10% after hours, following Makary’s post on X stating, “The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs.” His comments came after Hims introduced a compounded version of Novo Nordisk’s Wegovy weight-loss medication.
6 February 2026
····
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Shares of Hims & Hers Health Inc swung sharply Thursday following the company’s announcement that it plans to offer a low-cost compounded version of Novo Nordisk’s new Wegovy weight-loss pill. Novo Nordisk promptly threatened legal action. The stock bounced back to $24.41 in late morning trading after earlier surging to $29.44.
5 February 2026
···
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

“It’s never been more clear that we are delivering exactly what millions of people have been waiting for,” said HIMS CEO Andrew Dudum after Q2 results investors.hims.com. With analysts ranging from “Sell” to “Buy”, and social media buzzing, Hims & Hers remains one of 2025’s most talked-about healthcare stocks – its fortunes tightly tied to both the telehealth boom and regulatory oversight.
29 September 2025
·
Go toTop